Financial Data and Key Metrics Changes - Revenue for the second quarter reached $31.4 million, representing a 15% increase compared to the previous year, driven by strong Tableau console sales and consistent utilization [6][20] - Recurring revenue from consumables and services was $22.5 million, an 11% increase year-over-year [6][21] - Non-GAAP gross margin expanded to 38.4%, up more than one percentage point from last year [7][22] - Non-GAAP operating loss was $13.4 million, a 36% reduction from the prior year [24] - Net loss for the quarter was $18.5 million, down 46% from the previous year [24] Business Line Data and Key Metrics Changes - Product revenue was $23.1 million, with console revenue at $8.9 million and consumable revenue at $14.2 million, marking a 20% increase from the prior year [21] - Consumable revenue saw a 17% increase, contributing to the overall growth in recurring revenue [6] Market Data and Key Metrics Changes - Tableau is now utilized in over 900 acute and subacute sites across the United States, indicating strong market penetration [8] - A new enterprise agreement was secured with one of the largest national health systems, potentially placing hundreds of Tableau consoles [8] Company Strategy and Development Direction - The company aims to grow console revenue, expand gross margin, and drive towards profitability, with a focus on insourcing dialysis services [17][18] - The commercial organization has undergone significant transformation, enhancing sales processes and team capabilities to better target enterprise-level opportunities [11][72] - The company is optimistic about the market opportunity, particularly in the acute care sector, where penetration remains low [56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline and market demand, despite monitoring potential impacts from federal funding cuts in healthcare [13] - The company is on track to achieve cash flow breakeven and profitability, with a goal to use less than $50 million in cash for the year [15][28] Other Important Information - The company has produced over 1.5 million Tableau disposable treatments since bringing production in-house in 2023, which is crucial for quality and cost reduction [14] - The Chief Nursing Officer's role will focus on facilitating the transition from outsourcing to insourcing dialysis services, emphasizing the importance of nursing leadership in the sales process [50] Q&A Session Summary Question: Guidance and momentum for the second half of the year - Management acknowledged strong performance in the first half and expressed optimism for the second half, citing improvements in commercial transformation and high console utilization [32][36] Question: Status of Salesforce transition and productivity - Management confirmed that the commercial organization has significantly improved, with new tools and processes enhancing sales effectiveness [39][40] Question: Sustainability of deal strength and ASPs - Management indicated that strong ASPs are supported by high uptake of new products and a diversified pipeline, with enterprise agreements expected to drive future growth [45][48] Question: Focus of the new Chief Nursing Officer - The Chief Nursing Officer will work closely with the sales organization to facilitate the transition to insourcing, leveraging her experience to guide potential customers [50] Question: Outlook for cash burn into 2026 - Management provided limited guidance but indicated that cash burn may increase as production ramps up, with more detailed guidance expected later in the year [75]